Vaxcyte Reports Positive Phase 3 Data For VAX-31 Pneumococcal Vaccine

By Reuters News

- Vaxcyte, Inc. PCVX.O:

  • VAXCYTE REPORTS POSITIVE TOPLINE DATA FROM OPUS-1, THE PIVOTAL ADULT PHASE 3 TRIAL OF VAX-31, THE COMPANY’S 31-VALENT PNEUMOCOCCAL CONJUGATE VACCINE CANDIDATE

  • VAXCYTE - VAX-31 MEETS ALL PRESPECIFIED PRIMARY ENDPOINTS ACROSS AGE GROUPS COMPARED TO PCV20 AND/OR PCV21

  • VAXCYTE - VAX-31 WELL TOLERATED WITH SAFETY PROFILE SIMILAR TO PCV20 AND PCV21 ACROSS ALL AGES

  • VAXCYTE - VAX-31 MEETS NONINFERIORITY FOR ALL 32 SEROTYPE COMPARISONS IN ADULTS 18-49 VERSUS 50-64

  • VAXCYTE, INC.: TO REPORT RESULTS FROM OPUS-2 AND OPUS-3 ADULT PHASE 3 TRIALS IN FIRST HALF OF 2027

  • VAXCYTE - EXPECTS OPUS-2 AND OPUS-3 PHASE 3 TRIALS RESULTS IN H1 2027; BLA SUBMISSION PLANNED H1 2028

Further company coverage: PCVX.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk